Health Care & Life Sciences » Biotechnology | AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
80,856.00
124,384.00
418,276.00
532,091.00
609,946.00
474,002
Cost of Goods Sold (COGS) incl. D&A
11,960.00
20,306.00
89,562.00
129,418.00
198,885.00
217,505
Gross Income
68,896.00
104,078.00
328,714.00
402,673.00
411,061.00
256,497
SG&A Expense
76,013.00
97,095.00
197,855.00
277,742.00
366,917.00
320,650
EBIT
7,117.00
6,983.00
-
124,931.00
44,144.00
64,153
Unusual Expense
4,500.00
10,820.00
30,088.00
46,061.00
348,331.00
18,815
Non Operating Income/Expense
964.00
217.00
9,188.00
189.00
335.00
74
Interest Expense
-
14,697.00
53,251.00
73,153.00
68,382.00
51,971
Pretax Income
9,602.00
17,342.00
39,844.00
9,055.00
370,094.00
129,685
Income Tax
-
153,159.00
7,065.00
11,538.00
170,866.00
39,654
Consolidated Net Income
9,602.00
135,817.00
32,779.00
2,483.00
199,228.00
169,339
Net Income
9,602.00
135,817.00
32,779.00
2,483.00
199,228.00
169,339
Net Income After Extraordinaries
9,602.00
135,817.00
32,779.00
2,483.00
199,228.00
272,917
Net Income Available to Common
9,602.00
135,817.00
32,779.00
2,483.00
199,228.00
152,837
EPS (Basic)
0.44
5.38
0.93
0.07
5.71
1.91
Basic Shares Outstanding
21,703.00
22,416.00
31,471.00
34,346.00
34,907.00
34,394
EPS (Diluted)
0.44
5.38
0.93
0.07
5.71
1.91
Diluted Shares Outstanding
21,703.00
25,225.00
35,308.00
34,346.00
34,907.00
34,394
EBITDA
5,932.00
13,967.00
199,962.00
224,817.00
197,444.00
95,847
Non-Operating Interest Income
1,051.00
975.00
1,512.00
3,149.00
2,810.00
5,328

About AMAG Pharmaceuticals

View Profile
Address
1100 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.amagpharma.com
Updated 07/08/2019
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.